Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study

A. Sánchez-Montalvá, A. Fernández-Luque, C. P. Simeón, V. Fonollosa-Plà, A. Marín, A. Guillén, M. Vilardell

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

OBJECTIVES: To date, the diagnostic utility of anti-SSA/Ro52 autoantibodies in scleroderma and the association of them with certain clinical manifestations, particularly inflammatory myositis, are still controversial. This paper aims to assess the correlation between the presence of anti-SSA/Ro52 antibodies and the demographic, clinical and prognosis characteristics of patients with systemic sclerosis (SSc).METHODS: This is a retrospective, cross-sectional and observational study in patients with SSc. Baseline demographic and clinical characteristics were recorded. Presence of anti-SSA/Ro52, anti-SSA/Ro, anti-SSB/La, snRNP/Sm, anti-centromere, anti-Scl-70 and anti-PM-Scl were analysed by immunoblot, and antinuclear antibodies (ANA) by indirect immunofluorescence. Statistical analysis was performed with PASW Statics 18 software.RESULTS: A total of 132 consecutive patients with analysis of anti-SSA/Ro52 antibodies were selected from a Spanish cohort of 408 patients with SSc, 87.1% of them being women. About half of patients had the limited form (51.5%), followed by diffused form (18.9%), sclerosis sine scleroderma (22.7%), and pre-scleroderma (6.8%). Prevalence of anti-SSA/Ro52 was 35.6%. No association between anti-SSA/Ro52 and clinical manifestations was found, while detection of anti-SSA/Ro52 was significantly associated with the presence of anti-Ro.CONCLUSIONS: The results of our study show that anti-SSA/Ro52 antibodies are often found in SSc patients. No clinical manifestations, including inflammatory myopathy, were related with anti-SSA/Ro antibodies.
Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume32
Issue number6
Publication statusPublished - 1 Nov 2014

Fingerprint Dive into the research topics of 'Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study'. Together they form a unique fingerprint.

Cite this